Prognostic significance of magnetic resonance imaging of femoral marrow inpatients with myelodysplastic syndromes

Citation
S. Takagi et al., Prognostic significance of magnetic resonance imaging of femoral marrow inpatients with myelodysplastic syndromes, J CL ONCOL, 17(1), 1999, pp. 277-283
Citations number
36
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
JOURNAL OF CLINICAL ONCOLOGY
ISSN journal
0732183X → ACNP
Volume
17
Issue
1
Year of publication
1999
Pages
277 - 283
Database
ISI
SICI code
0732-183X(199901)17:1<277:PSOMRI>2.0.ZU;2-1
Abstract
Purpose: to investigate whether the abnormalities observed on femoral marro w magnetic resonance images are related to the development of leukemia and survival of patients with myelodysplastic syndromes (MDS). Patients and Methods: The findings on magnetic resonance images of the femo ral marrow were evaluated over periods of 1 to 92 months (median, 18 months ) in 42 consecutive adult patients with newly diagnosed MDS. Magnetic reson ance images were obtained by the T1-weighted spin echo method and the short TI inversion recovery technique, Results: Magnetic resonance images showed that the femoral marrow patterns changed from fatty, faint, or nodular to scattered or uniform as the diseas e progressed, Development of acute myeloid leukemia was observed in only 13 patients whose marrow exhibited a scattered or uniform pattern. The overal l survival of the 29 patients with a scattered or uniform marrow pattern wa s significantly shorter than that of the 13 patients with a fatty, faint, o r nodular marrow pattern (10.7% v 73.3% at 7 years; P < .01). The period of leukemia-free survival was also significantly shorter in the patients with a scattered or uniform marrow pattern versus a fatty, faint, or nodular pa ttern (37.7% v 100% at 7 years; P < .01). Conclusion: Magnetic resonance images of the femoral marrow can provide val uable information for assessing the prognosis and determining the most appr opriate management of patients with MDS. J Clin Oncol 17:277-283. (C) 1999 by American Society of Clinical Oncology.